The SMA-TB project, an initiative funded by the European Commission's H2020 programme (GA No. 847762), has reached its conclusion after five years of research aimed at improving tuberculosis (TB) treatments. Coordinated by the Experimental Tuberculosis Unit (UTE) at the Germans Trias i Pujol Research Institute (IGTP), the project has explored how Host-Directed Therapies (HDT) can shorten treatment duration and improve outcomes by reducing excessive inflammation without generating additional drug resistance.
The project's key achievements include:
According to Cristina Vilaplana, project coordinator and principal investigator at IGTP's UTE: "Despite numerous challenges, including the COVID-19 pandemic and unforeseen changes within the consortium, we have successfully completed this project. The work carried out lays the foundation for future research and innovation in tuberculosis treatment".
The main scientific publications derived from the project will be released soon. In the meantime, further information is available through the following resources: